Ziconotide Dosing & Reconstitution Guide

Ziconotide is administered via intrathecal infusion, specifically through an implanted pump designed for continuous delivery. The dosing range for Ziconotide varies from 2.4 to 19.2 mcg per day, reflecting the need for individualized titration based on patient response and tolerance. Studies indicate that careful titration is critical, as the initial dose should not exceed 2.4 mcg per day, with subsequent increases limited to the same amount and spaced no less than 2 to 3 times per week. This approach is essential for minimizing central nervous system (CNS) adverse effects, which can be significant in this patient population.

The safety profile of Ziconotide reveals several common adverse effects experienced by at least 10% of patients, including dizziness (47%), nausea (30%), confusion (33%), and headache (15%). Additional effects such as somnolence, nystagmus, abnormal gait, and memory impairment have also been reported. More severe neuropsychiatric effects, including cognitive impairment, hallucinations, and suicidal ideation, have occurred, emphasizing the importance of careful monitoring. Ziconotide must be delivered exclusively via an intrathecal pump, and due to its potent effects, a conservative titration schedule is crucial to mitigate potential CNS complications. Contraindications include a history of psychosis or severe psychiatric disorders, as these conditions may be exacerbated by Ziconotide treatment, along with hypersensitivity to the compound.